U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARD Modulator being Developed for the Treatment of Primary Mitochondrial Myopathies October 26, 2020
FDA Grants Fast Track Designation for the Development of Mitobridge’s ASP1128 for Patients at Risk for Acute Kidney Injury November 4, 2019
